azacitidine and alpha-aminopyridine

azacitidine has been researched along with alpha-aminopyridine in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (58.33)24.3611
2020's5 (41.67)2.80

Authors

AuthorsStudies
Gao, X; Jiang, M; Ning, Q; Wang, J; Wang, L; Yao, Y; Yu, L; Zhou, J1
Albert, DH; Ansell, P; Arellano, M; Garcia-Manero, G; Kadia, T; Kantarjian, H; Khoury, HJ; Knight, EA; McKee, MD; Munasinghe, W; Oliver, B; Qin, Q; Ricker, JL; Roberts-Rapp, L; Tibes, R; Xiong, H1
Garrett-Bakelman, FE; Glass, J; Gliser, C; Intlekofer, AM; Knapp, K; Levine, RL; Mason, CE; Melnick, A; Meydan, C; Nazir, A; Shank, K; Shih, AH; Stein, EM; Straley, K; Thompson, CB; Travins, J; Ward, PS; Yen, K1
Chen, K; Deng, M; Guo, X; Jiang, Z; Li, P; Shi, P; Xu, B; Zha, J; Zhang, L1
Fan, Y; Guo, F; Song, D; Sun, Q; Wang, J; Wang, L; Zhang, D; Zhang, Q; Zhang, W1
Hoffmann, M; Surapaneni, S; Tong, Z; Yao, S; Yerramilli, U; Young, JD1
Estey, EH; Percival, MM1
Naoe, T1
Avanzino, B; Chopra, VS; DiMartino, JF; Figueroa, ME; MacBeth, KJ; Quek, L; Schwickart, M; See, WL; Tang, L; Zheng, B1
Bennett, JM; de Botton, S; DiNardo, CD; Döhner, H; Fathi, AT; Frattini, MG; Gong, J; Hasan, M; Kantarjian, HM; Lersch, F; Martin-Regueira, P; Montesinos, P; Schuh, AC; Stein, EM; Vyas, P; Wei, AH; Zeidan, AM1
Fu, JH; Li, JL; Li, Z; Qiu, HY; Qiu, QC; Xue, SL; Zhang, J; Zhou, M1
Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H1

Reviews

3 review(s) available for azacitidine and alpha-aminopyridine

ArticleYear
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
    Cancer, 2019, Sep-15, Volume: 125, Issue:18

    Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles

2019
<Editors' Choice> How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
    Nagoya journal of medical science, 2020, Volume: 82, Issue:2

    Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines

2020
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
    Current problems in cardiology, 2022, Volume: 47, Issue:11

    Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration

2022

Trials

2 trial(s) available for azacitidine and alpha-aminopyridine

ArticleYear
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
    Investigational new drugs, 2015, Volume: 33, Issue:4

    Topics: Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Azacitidine; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor

2015
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    The Lancet. Oncology, 2021, Volume: 22, Issue:11

    Topics: Aged; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Progression-Free Survival; Random Allocation; Treatment Outcome; Triazines

2021

Other Studies

7 other study(ies) available for azacitidine and alpha-aminopyridine

ArticleYear
Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Aminopyridines; Antigens, Neoplasm; Apoptosis; Azacitidine; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; HLA-A Antigens; Humans; Leukemia, Myeloid, Acute; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic

2013
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
    Cancer discovery, 2017, Volume: 7, Issue:5

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mice; Mice, Mutant Strains; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins; Signal Transduction; Triazines

2017
Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage.
    Pharmacogenomics, 2017, Volume: 18, Issue:13

    Topics: Adolescent; Adult; Aminopyridines; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Damage; Female; Gene Deletion; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Young Adult

2017
Hypermethylated CD36 gene affected the progression of lung cancer.
    Gene, 2018, Dec-15, Volume: 678

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; CD36 Antigens; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Invasiveness; Xenograft Model Antitumor Assays

2018
    Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:10

    Topics: Aminopyridines; Animals; Azacitidine; Cell Line; Humans; Isocitrate Dehydrogenase; Nucleoside Transport Proteins; Triazines; Xenopus laevis

2019
Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.
    Experimental hematology, 2021, Volume: 98

    Topics: Aminopyridines; Azacitidine; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Triazines

2021
Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
    Oncology reports, 2022, Volume: 47, Issue:4

    Topics: Aminopyridines; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Synergism; Epigenomics; Humans; Leukemia, Myeloid, Acute; U937 Cells; Up-Regulation

2022